Dr Clara Chow (Professor of Medicine, Academic Director Westmead Applied Research Centre, University of Sydney, Sydney, Australia) kindly shared her thoughts on the limitations of current treatment paradigms for hypertension, the quad pill for hypertension, and the QUARTET study, from the virtual ESC Congress 2021.
- What are the limitations of current treatment paradigms for hypertension? (0.18)
- What is the composition of the quad pill for hypertension, and what is the rationale for its use? (1.26)
- What have clinical studies to date taught us about the efficacy and safety of this approach? (2.38)
- What were the aims, design and eligibility criteria of the QUARTET study? (3.41)
- What are the strengths and limitations of this study? (6.01)
Speaker disclosures: Dr Clara Chow has nothing to declare in relation to this video interview.
Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.
Filmed during a remote video call with Dr Clara Chow as a highlight of ESC 2021, August 2021.
Share this Video
Related Videos In Hypertension
Kelly Chin, ACC 2023: The treatment paradigm for patients with pulmonary arterial hypertension
Recommended therapy for patients with pulmonary arterial hypertension is generally a combination of an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the treatment paradigm. Dr Chin presented an abstract entitled ‘Efficacy And Safety Of […]
Kelly Chin, ACC 2023: A DUE phase III study, a macitentan and tadalafil combination for patients with pulmonary arterial hypertension
The aim of the A DUE study was to assess the combination of macitentan and tadalafil for patients with pulmonary arterial hypertension. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the findings of the trial and the clinical impact. The abstract entitled ‘Efficacy And […]
Marius Hoeper, ACC 2023: STELLAR phase III trial results – Sotatercept for the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressive disease involving proliferative remodeling of the pulmonary vessels and elevations in pulmonary vascular resistance (PVR). Despite recent treatment advances, the associated morbidity and mortality rates of the disease are still high. In this touchCARDIO interview, we speak with Prof. Marius Hoeper (Department of Respiratory Medicine, Hannover Medical School, Hannover, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!